Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:
What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
Predictions from the panel around the future of deal flow in the outsourcing space… will the current velocity continue?
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.
We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com
The servant leader creating the next generation CDMO